Tag Archive for: pulmonary fibrosis. idiopathic pulmonary fibrosis

Vicore and Nippon Shinyaku Enter into an Exclusive License Agreement to Develop and Commercialize C21 in Japan

/in

C21 is a potentially transformative therapy for the treatment of idiopathic pulmonary fibrosis (IPF) Vicore to receive USD 10 million upfront and is entitled to up to USD 275 million in milestones in addition to tiered royalty payments Nippon Shinyaku has been granted exclusive rights to and will be responsible for development of C21 in […]

Read more

Vicore obtains significant new patent protection for C21 in the US

/in

Stockholm, May 23, 2023 – Vicore Pharma Holding AB (STO:VICO) (“Vicore”) today announces issuance of a new US patent protecting an improved C21 formulation based on enteric coated compositions. The drug candidate C21 is currently in a phase 2a trial in idiopathic pulmonary fibrosis (IPF). The patent provides strong protection in the US because the […]

Read more